ReviewOncoTargets and therapy2016

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.

Jacqueline C BarrientosPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.